Literature DB >> 23153241

Methylation of tumor suppressor microRNAs: lessons from lymphoid malignancies.

Lu Qian Wang1, Raymond Liang, Chor Sang Chim.   

Abstract

miRNAs are a group of small noncoding RNAs measuring 19-25 nucleotides. Sequence-specific binding of miRNAs to the 3´ untranslated regions of target genes leads to translational repressions. Dysregulation of miRNA expression involved in cancer can be triggered by multiple mechanisms including aberrant DNA methylation of the miRNA gene promoter. Of note, DNA methylation of tumor suppressor miRNAs has been implicated in various human cancers. Moreover, miRNA silencing mediated by aberrant promoter DNA methylation can potentially be reversed by hypomethylating agents, and hence may pose a new therapeutic target in cancer. In this review, the authors will focus on the aberrant methylation of miRNAs in the pathogenesis of lymphoid malignancies including chronic lymphocytic leukemia, multiple myeloma and acute lymphoblastic leukemia.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23153241     DOI: 10.1586/erm.12.64

Source DB:  PubMed          Journal:  Expert Rev Mol Diagn        ISSN: 1473-7159            Impact factor:   5.225


  8 in total

1.  Involvement of microRNA-24 and DNA methylation in resistance of nasopharyngeal carcinoma to ionizing radiation.

Authors:  Sumei Wang; Rong Zhang; Francois X Claret; Huiling Yang
Journal:  Mol Cancer Ther       Date:  2014-10-15       Impact factor: 6.261

2.  A study on the correlation between MTHFR promoter methylation and diabetic nephropathy.

Authors:  Xiao-Hui Yang; Ren-Fang Cao; Yang Yu; Miao Sui; Tao Zhang; Jing-Yi Xu; Xiao-Mei Wang
Journal:  Am J Transl Res       Date:  2016-11-15       Impact factor: 4.060

3.  Reversal of microRNA-150 silencing disadvantages crizotinib-resistant NPM-ALK(+) cell growth.

Authors:  Coralie Hoareau-Aveilla; Thibaud Valentin; Camille Daugrois; Cathy Quelen; Géraldine Mitou; Samuel Quentin; Jinsong Jia; Salvatore Spicuglia; Pierre Ferrier; Monica Ceccon; Sylvie Giuriato; Carlo Gambacorti-Passerini; Pierre Brousset; Laurence Lamant; Fabienne Meggetto
Journal:  J Clin Invest       Date:  2015-08-10       Impact factor: 14.808

Review 4.  Role of microRNAs in gastric cancer.

Authors:  Hideyuki Ishiguro; Masahiro Kimura; Hiromitsu Takeyama
Journal:  World J Gastroenterol       Date:  2014-05-21       Impact factor: 5.742

Review 5.  MicroRNAs: new players in IBD.

Authors:  R Kalla; N T Ventham; N A Kennedy; J F Quintana; E R Nimmo; A H Buck; J Satsangi
Journal:  Gut       Date:  2014-12-04       Impact factor: 23.059

6.  Epigenetic silencing of tumor suppressor miR-3151 contributes to Chinese chronic lymphocytic leukemia by constitutive activation of MADD/ERK and PIK3R2/AKT signaling pathways.

Authors:  Lu Qian Wang; Kwan Yeung Wong; Anders Rosèn; Chor Sang Chim
Journal:  Oncotarget       Date:  2015-12-29

7.  Epigenetic inactivation of miR-9 family microRNAs in chronic lymphocytic leukemia--implications on constitutive activation of NFκB pathway.

Authors:  Lu Qian Wang; Yok Lam Kwong; Chi Shan Bonnie Kho; Kit Fai Wong; Kwan Yeung Wong; Manuela Ferracin; George A Calin; Chor Sang Chim
Journal:  Mol Cancer       Date:  2013-12-27       Impact factor: 27.401

8.  Methylation profiling of SOCS1, SOCS2, SOCS3, CISH and SHP1 in Philadelphia-negative myeloproliferative neoplasm.

Authors:  Min Yue Zhang; Tsz Kin Fung; Fang Yuan Chen; Chor Sang Chim
Journal:  J Cell Mol Med       Date:  2013-10-16       Impact factor: 5.310

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.